Transcriptomic changes in a KRASG12C mutant cell line (H358 cells) treated with the allosteric SHP2 inhibitor TNO155 for different times

Allosteric SHP2 inhibitors have been shown to be effective against RTKs and certain KRAS mutation-driven tumors in preclinical models. However, the comprehensive effects of SHP2 inhibitors on cellular signaling, particularly the inhibition of its phosphatase function, remain unclear. Overall design: We used the SHP2 inhibitor TNO155 (1 µM) to treat the KRASG12C mutated H358 cells for different times (4, 24, 48 h), with DMSO treatment serving as a control, and then utilized RNA-seq to explore the impact of SHP2 inhibition on gene expression and signaling pathways.